Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
In studies of GLP-1RA therapy in individuals with type 2 diabetes, the most frequently reported adverse events tend to involve the gastrointestinal system, with nausea, vomiting, and diarrhea occurring in up to 51%, 19%, and 20% of patients, respectively [44]
No material is intended to be a substitute for professional medical advice, diagnosis, or treatment.
This study also showed a non-significant 17% reduction in albuminuria.67 The AWARD-7 study analyzed the efficacy of dulaglutide in patients with DM2 and moderate-severe CKD (mean eGFR 38 ml/min/1.73 m2)
Perspectives and conclusions Tirzepatide has demonstrated marked and dose-dependent reductions in glycemic parameters in patients with T2D that, according to the present study data, surpass the effects of the GLP-1RA dulaglutide and semaglutide (66, 67, 71)
